Cardinal Health Inc (CAH)

Cardinal Health Inc. has garnered mixed reviews from experts, reflecting a balance of optimism and caution regarding its recent acquisition of a urology company. One analyst appreciates the purchase, projecting a target price of $300, while highlighting the company’s role as one of the three major distributors in healthcare and how the aging population, as well as increased prescriptions, create favorable long-term growth conditions. Furthermore, the stock is currently trading at a forward price-to-earnings ratio of 16x with a promising 13% earnings per share growth, suggesting a nearly 1x PEG ratio, emphasizing its potential. However, concerns have arisen since the acquisition of Solaris, leading to a temporary dip in stock prices, which some view as a buying opportunity. With a yield of 1.35% and consistent earnings growth, the outlook remains cautiously optimistic while analysts have varying price targets, averaging around $180.71.